Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common blood thinner beat staph infections? new trial investigates

NCT ID NCT06650501

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 27 times

Summary

This study looks at whether switching to a blood thinner called dabigatran can help people with a serious staph bloodstream infection. Participants are adults already taking a different blood thinner (apixaban, edoxaban, or rivaroxaban) for conditions like atrial fibrillation or blood clots. Half will continue their current medication, and half will switch to dabigatran, which has shown promise against staph bacteria in lab and animal studies. The goal is to see if dabigatran leads to fewer complications or deaths.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS AUREUS BACTEREMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

    RECRUITING

    Montreal, Quebec, H4A3S1, Canada

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.